Palatin_Technologies_Updates_2025 (1).pptx

palatin technologies updates

1. Palatin Technologies Updates and Expected Milestones for 2025 - Obesity Programs: - Phase 2 BMT-801 Clinical Study: Topline results expected in Q1 2025 for the co-administration of bremelanotide with tirzepatide to reduce body weight. - New Clinical Trials: Multiple trials targeting general obesity, weight loss management, and rare neuroendocrine and genetic diseases set to commence in the second half of 2025. - Other Programs: - Dry Eye Disease and Ocular Programs: Ongoing licensing, collaboration, and spinout discussions with multiple deals targeted for 2025. - Ulcerative Colitis and Diabetic Nephropathy Programs: Similar discussions and potential deals expected within the year.